《美股业绩》吉利德季绩逊预期 瑞德西韦销售未抵销丙型肝炎药倒退
瑞德西韦药物生产商吉利德科学(Gilead Sciences)(GILD.US)公布第二季度业绩。季度亏损33.39亿美元,对上年度同期纯利18.8亿美元。每股季度摊薄亏损2.66美元,经调整後为1.11美元,差於市场预期的1.45美元。季度收入51.43亿美元,按年跌10%,差於市场预期的53亿美元。主要受丙型肝炎药及爱滋病毒销售在疫情下疲弱拖累。
公司预期全年销售介乎230亿至250亿美元,高於原来预测的介乎218亿至222亿美元。
公司股价在延长交易时段跌3.2%,报70美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.